Can a simple ultrasound spot liver cancer treatment success faster?

NCT ID NCT07145801

Recruiting now Diagnosis Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients and compare CEUS images to standard scans at 1-2 and 4-6 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lumason (sulfur hexafluoride lipid microspheres, an ultrasound contrast agent)
What this could lead to: If successful, this could make it faster and more accurate to see if liver cancer treatment worked, helping doctors decide on retreatment sooner.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The ultrasound technique may not be better than current scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma hepatocellular carcinoma liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC HEPATIC NEOPLASM HEPATOCELLULAR CARCINOMA LIVER CANCER LIVER NEOPLASM PRIMARY LIVER CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.